Draganfly Inc. to start supplying needle-free injection devices and insulin from NuGen Medical Device to Ukrainian type 1 diabetics in urgent need of supply

0

Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.


Revived soldiers in Ukraine deploy Draganfly’s medical response drones to deliver NuGen MD’s needleless injection devices, paired with insulin, to conflict zones across Ukraine

TORONTO, ON/ACCESSWIRE/May 12, 2022/ NuGen Medical Devices Inc. (TSXV: NGMD) (“NuGen” or the “Company”), a leader in needle-free drug delivery, is pleased to announce that the Company has selected Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly”), an award-winning developer of industry-leading drone solutions and systems, and Coldchain Delivery Systems, Inc. (“Coldchain Delivery Systems”) to provide drones and services for the delivery of NuGen’s needle-free drone injection system, known as InsuJet, insulin and other essential medical supplies to affected areas in Ukraine.

Work with Risen soldiers Ukraine (“RSU”), a non-profit organization dedicated to helping the people of Ukraine, Draganfly’s North American-made medical response drones will be used to deliver NuGen’s InsuJet needle-free injection devices, associated insulin, dangerous people and hard-to-reach areas across Ukraine.

“There is an urgent need for insulin and other life-saving medical supplies across Ukraine. The combination of our medical response drones and NuGen’s easy-to-use needleless injectors, preloaded with insulin, will ensure that RSU can provide Ukrainians with diabetes with the help they need,” said Cameron Chell, President and CEO of Draganfly.

Watch the video below for an exclusive interview with Ms. Vaschuk Discipio and learn how the initiative will save lives as RSU and Draganfly prepare for the first insulin delivery.

Watch the interview here.

A recent CNN[1]article by Tasnim Ahmed, published March 18, 2022, reported that although Ukraine has an adequate supply of insulin to last up to three months, access to supplemental insulin is limited and type 1 diabetics in the high-conflict areas are cut off from the insulin supply. This supply is rapidly diminishing.

There are approximately 2.3 million people with diabetes in Ukraine[2], some of whom are type 1 diabetics who need several daily injections of insulin to survive. However, for those living in high-conflict areas of the country, access to life-saving insulin is limited or non-existent. Because insulin is a temperature-sensitive commodity, rapid and safe transport of insulin is a top priority, making it difficult to deliver the drug to conflict areas.

Not only are vital medical supplies like insulin dwindling, but there is an urgent need as hospitals across Ukraine come under direct attack. There have been 72 attacks on health facilities as Russia targets not only primary care centers but also children’s hospitals and maternity wards across the country in a ‘criminal campaign’, reports Scott Pelley in a 60 minutes special[3]. The attacks, which occur daily, have left many dead and even more injured, including medical professionals, patients and visitors, further underscoring the atrocities and the need for medical support for the Ukrainian people.

Draganfly recently announced that its first medical response drone was received by Iryna Vashchuk Discipio, President of RSU, and members of her staff, including pilots, at a facility in Poland on May 1, 2022. The drone then was flown to Ukraine, where the company’s experienced pilots conducted virtual training with RSU drone operators.

Draganfly’s medical response drone is capable of carrying up to 35 pounds. When equipped with the company’s temperature-managed medical response payload box, the drone can carry temperature-sensitive medical supplies including insulin/drugs, blood, pharmaceuticals, vaccines, water and wound care kits. The innovative payload system of this type of drone guarantees ease of access when mounted on the top and efficient quick release operations when mounted on the bottom.

NuGen’s initial donation will consist of 50 InsuJet needleless injection devices and 5,000 needleless disposable syringes filled with insulin. Each device can be used safely 5,000 times without risk of needle stick injury or cross contamination. free injection device has been approved by Health Canada and holds a CE mark for sale throughout Europe.

“At NuGen, we believe that every individual should have the opportunity to receive respectful, safe and nurturing healthcare. Since tragedy struck Ukraine, we have been looking for ways to help,” said Michael Wright, president and CEO of NuGen Medical. Devices Inc. “We are grateful to be working with Draganfly, Coldchain Delivery Systems and RSU along with the fundraising efforts of KIN Communications to ensure Ukrainians in need have access to essential medical supplies and equipment.”

Donors wishing to make charitable donations to the cause can visit www.droneaid.co

Click here to learn more about fundraising efforts in Ukraine.

About NuGen Medical Devices

NuGen Medical Devices’ core business is the development and commercialization of innovative needle-free injection devices and systems for subcutaneous drug delivery.

It develops products using needle-free drug delivery technology in several important areas, including but not limited to anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines.

For more information visit: www.nugenmd.com
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/

For more information, please contact:

Michael Wright
President and CEO
NuGen Medical Devices Inc.
[email protected]
(514) 992-9484

To arrange a media interview with NuGen MD, contact:

Nelson Hudes
Hudes Communications International
(905) 660-9155
[email protected]

Contact with Investor Relations:
Kin Communications Inc.
[email protected]
(604) 684-6730

Twitter: @KinComm

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is the creator of quality, cutting-edge drone, software and artificial intelligence systems solutions that are revolutionizing the way organizations can do business and serve their stakeholders. Recognized as being at the forefront of technology for over 20 years, Draganfly is an award-winning industry leader serving the markets of public safety, public health, mining, agriculture, industrial inspections, security, mapping and surveying. Draganfly is a company driven by passion, ingenuity and the need to provide effective solutions and first-class services to its customers around the world with the aim of saving time, money and lives.

For more information about Draganfly, please visit us at www.draganfly.com.

For more information on investors, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.nasdaq.com/market-activity/stocks/dpro or https://www.boerse-frankfurt.de/equity/draganfly-inc-1.

Media Contact

Arian Hopkins
E-mail: [email protected]

Company details

E-mail: [email protected]

About Coldchain Delivery Systems

Coldchain Delivery Systems is the leader in time and temperature sensitive medical device management, integrating proven systems with fundamental documentation for accreditation and effective quality control systems. Coldchain Delivery Systems’ remote monitoring system, prequalified thermal shippers, inventory control, fulfillment and QAQC solutions ensure the integrity and safety of its client’s product.

For more information visit: https://coldchain-tech.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking information that is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward-looking statements in this press release include the Company’s 2022 goals to enter into additional distribution and sales agreements, submit applications for regulatory approvals and take advantage of additional market opportunities. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

THE SOURCE: NuGen Medical Devices

See the source version on accesswire.com:
https://www.accesswire.com/701124/Draganfly-Inc-to-Begin-Delivering-NuGen-Medical-Devices-Needle-Free-Injection-Devices-and-Insulin-to-Ukraine-Type-1-Diabetics- Urgent need for supply

Share.

About Author

Comments are closed.